Archives

2008

• April, 10 2008 | view pdf
  Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA

2007

• November, 1 2007 | view pdf
  Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies

2006

• December, 12 2006 | view pdf
  Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors
  
  
• January, 19 2006 | view pdf
  Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia

2005

• December, 20 2005 | view pdf
  Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd., as Phase 2 Studies Initiate in Japan on First-in-Class Antibiotic EDP-420 (S-013420) for the Treatment of Community Acquired Pneumonia
  
  
• May, 19 2005 | view pdf
  Chiron and Enanta Pharmaceuticals Announce Agreement for Development and Commercialization of HCV Therapeutics
  
  
• March, 14 2005 | view pdf
  Enanta Pharmaceuticals Achieves Milestone in Collaboration with Shionogi & Co., Ltd., as Phase 1 Studies Initiate in Japan on EDP-420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic
  
  
• February 22, 2005 | view pdf
  Enanta Pharmaceuticals Appoints Pharmaceutical Veteran David Poorvin, Ph.D. to Board of Directors and Announces Key Hire to Clinical Development Team

2004

• August 31, 2004 | view pdf
  Enanta Pharmaceuticals Raises $20 Million in New Financing and Initiates Phase 1 Clinical Trial on EDP-420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic for Community Respiratory Tract Infections
  
  
• July 27, 2004 | view pdf
  Enanta Pharmaceuticals and Shionogi & Co., Ltd. Sign Agreement for Development and Commercialization of the First-in-Class Bridged Bicyclic Ketolide Antibiotic EDP-420 in Japan and East Asian Countries
  
  
• January 14, 2004 | view pdf
  Enanta Pharmaceuticals Secures $12 Million Financing Under New Management
  

2003

• September 15, 2003 | view pdf
  Enanta Pharmaceuticals Presents Macrolide and Ketolide Antibiotic Data in 12 Poster Presentations at ICAAC 2003
  
  
• July 18, 2003 | view pdf
  Enanta Pharmaceuticals Introduces New Macrolide Class at ISAAR 2003
  
  
• June 17, 2003 | view pdf
  Enanta Pharmaceuticals Awarded Fourth Patent Covering Novel Macrolide Antibiotics
  
  
• May 19, 2003 | view pdf
  Novel Cyclosporine Analogs with Reduced Toxicity Data Presented by Enanta Pharmaceuticals at FOCIS 2003
  
  
• March 25, 2003 | view pdf
  Enanta Pharmaceuticals Introduces New Macrolide Class at Antibacterial Drug Discovery & Development Summit
  
  
• March 12, 2003 | view pdf
  Chiron Corporation Exercises License to Enanta Pharmaceuticals Compounds
  
  
• February 5, 2003 | view pdf
  Enanta Pharmaceuticals Presents Cyclosporin and Macrolide Chemistry and application of Peptide Morphing™ Technology in Three Scientific Papers
  

2002

• October 29, 2002 | view pdf
  Enanta Pharmaceuticals Presents R&D at Mass Opps Investor Conference
  
  
• October 23, 2002 | view pdf
  Enanta Pharmaceuticals Appoints Yujiro Hata to Vice President of Business Development
  
  
• October 9, 2002 | view pdf
  Enanta Pharmaceuticals Awarded Three US Patents for Novel Macrolide Antibiotics
  
  
• October 2, 2002 | view pdf
  Enanta Pharmaceuticals Appoints Robert Kamen to Company's Scientific Advisory Board
  
  
• September 30, 2002 | view pdf
  Enanta Pharmaceuticals Presents Macrolide Antibiotic Research at the Annual 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy
  
  
• September 4, 2002 | view pdf
  Enanta Pharmaceuticals signs Collaboration Agreement with Chiron Corporation for Hepatitis C Therapeutics
  
  
• Aug. 21, 2002 | view pdf
  Enanta Pharmaceuticals presents single-step chemistry technology enabling synthesis of novel Cyclosporin A soft drug derivatives for treating asthma
  
  
• July 1, 2002 | view pdf
  Enanta Pharmaceuticals Presents Safety Data On Novel Cyclosporin-A Analogs for Asthma
  
  
• June 12, 2002 | view pdf
  Enanta Pharmaceuticals raises $18 million in latest round of private equity financing
  
  
• May 22, 2002 | view pdf
  Enanta Pharmaceuticals presents data from collaborative study with University of Pittsburgh Medical Center that confirm its new class of cyclosporin analogs have potent anti-inflammatory effects targeted to asthma
  

2001